华盛顿，10月12日 - 药企Corcept Therapeutics正寻求排除一名退休联邦上诉法院法官的证词，该法官在反垄断诉讼中支持Teva制药。Corcept认为，该法官的意见可能影响陪审团，却无助于澄清案件事实。
WASHINGTON, Oct 12 - Drugmaker Corcept Therapeutics is seeking to exclude testimony from a retired federal appeals court judge supporting Teva Pharmaceuticals in an antitrust lawsuit, arguing her opinions could sway jurors without shedding light on the facts of the case.
Corcept在周五向加州联邦法院提交的文件中表示，顾问兼美国联邦巡回上诉法院退休法官Kathleen O’Malley未提供任何技术专长，且其法律意见的陈述不恰当。
filing on Friday in federal court in California, Corcept said consultant and retired judge Kathleen O’Malley of the US Court of Appeals for the Federal Circuit offered no technical expertise and that her presentation of legal opinions was inappropriate.
“鉴于O’Malley法官曾是司法官员，她对陪审团的越权行为尤为有害，”Corcept表示。“陪审团可能不会意识到她在案件事实方面没有任何技术专长，而赋予她的证词不应有的权重，尽管她的意见最终仅仅是她认为陪审团应如何裁决。”Teva、Corcept和O’Malley均未立即回应置评请求。
"Judge O’Malley’s usurpation of the jury is particularly harmful given her position as a former jurist," Corcept said. "It is likely that the jury will not understand she brings no technical expertise in any factual area in the case and give her testimony undue weight, even though her opinions are ultimately just how she thinks the jury should decide." Teva, Corcept and O’Malley did not immediately respond to requests for comment.
Teva于2024年起诉Corcept，称其垄断了用于治疗库欣综合征的药物Korlym市场。诉讼称，Teva因推广Korlym的仿制药版本而遭受“可观的收入损失”，要求未具体说明的金钱赔偿，并申请法院命令阻止Corcept所谓的反竞争行为。
Teva sued Corcept in 2024, claiming it monopolized the market for the drug Korlym to treat the hormonal disorder Cushing's syndrome. The lawsuit said Teva suffered "substantial lost revenue" from its efforts to market a generic version of Korlym, and seeks unspecified monetary damages and a court order stopping Corcept's alleged anti-competitive conduct.
Korlym的活性成分是米非司酮，与用于药物流产的药物相同。Corcept已否认这些指控。
Korlym's active ingredient is mifepristone, the same drug used for medication abortion. Corcept has denied the allegations.
O’Malley在该案中以Teva的专家身份提交了一份报告，称Corcept提交了“假冒”的专利侵权诉讼。Teva的诉讼指控Corcept通过提起虚假诉讼来阻碍Teva的Korlym仿制药版本的竞争。
O’Malley submitted a report as an expert for Teva in the case that said Corcept had filed “sham” patent infringement cases. Teva's lawsuit alleges Corcept pursued bogus lawsuits to thwart competition from Teva's generic version of Korlym.
O’Malley曾于2010年至2022年在美国华盛顿特区的联邦巡回上诉法院任职。此后，她曾在Irell及Sullivan & Cromwell律师事务所工作，随后创办了自己的咨询公司，该公司包括为企业在诉讼中担任专家证人。
O’Malley served on the Washington, DC-based Federal Circuit from 2010 to 2022. She later worked at law firms Irell and Sullivan & Cromwell before opening her own consulting business that includes appearing as an expert for companies in lawsuits.
Corcept 认为，奥马利的专家报告对潜在陪审员没有提供任何帮助，无法让他们像医生就所声称发明的范围作证那样理解诉讼中的主张。
Corcept contends O'Malley's expert report offered potential jurors no help understanding the claims in the lawsuit, in the way a doctor might testify about the scope of a claimed invention.
“相反，特瓦已聘请一名前联邦法官来为它完成陪审团的工作，”昆恩伊曼律所代表 Corcept 的律师表示。
“Instead, Teva has hired a former federal judge to do the jury’s job for it,” Corcept’s lawyers at Quinn Emanuel said.
此案为 Teva Pharmaceuticals USA Inc. v. Corcept Therapeutics Inc. et al，美国加利福尼亚州北区地方法院，案号 5:24-cv-03567-NW。
The case is Teva Pharmaceuticals USA Inc. v. Corcept Therapeutics Inc. et al, US District Court, Northern District of California, No. 5:24-cv-03567-NW.
特瓦方：Kirkland & Ellis 律所的 Devora Allon、Kevin Neylan Jr 和 Michael Shipley Corcept 方：Quinn Emanuel Urquhart & Sullivan 律所的 Robert Stone、Adam Wolfson 和 Steig Olson
For Teva: Devora Allon, Kevin Neylan Jr and Michael Shipley of Kirkland & Ellis For Corcept: Robert Stone, Adam Wolfson and Steig Olson of Quinn Emanuel Urquhart & Sullivan